5 Simple Techniques For Arecoline
MI-CP151 was a phase 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study To guage various intravenous doses of sifalimumab, in adult people with dermatomyositis or polymyositis (NCT00533091). Most important demo objectives have been To guage the protection and tolerability of sifalimumab in dermatomyositis or polymyosit